Adagene Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAG research report →
Companywww.adagene.com
Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors.
- CEO
- Peter Luo
- IPO
- 2021
- Employees
- 138
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $129.89M
- P/E
- -7.41
- P/S
- 16.88
- P/B
- 3.70
- EV/EBITDA
- -2.95
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.43%
- Op Margin
- -279.39%
- Net Margin
- -229.49%
- ROE
- -48.20%
- ROIC
- -36.34%
Growth & Income
- Revenue
- $7.67M · 7332.76%
- Net Income
- $-17,609,413 · 47.32%
- EPS
- $-0.46 · 51.32%
- Op Income
- $-21,438,295
- FCF YoY
- 47.29%
Performance & Tape
- 52W High
- $4.75
- 52W Low
- $1.30
- 50D MA
- $3.78
- 200D MA
- $2.55
- Beta
- 0.57
- Avg Volume
- 236.25K
Get TickerSpark's AI analysis on ADAG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 0 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 0 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 400,000 |
| Mar 18, 26 | Chane-Du Mickael Yannick | other | 400,000 |
| Mar 2, 26 | Chane-Du Mickael Yannick | other | 250,000 |
| Mar 18, 26 | Tam Man Kin | other | 0 |
| Mar 18, 26 | Tam Man Kin | other | 0 |
| Mar 18, 26 | Tam Man Kin | other | 100,000 |
| Mar 18, 26 | Tam Man Kin | other | 50,000 |
| Mar 18, 26 | Tam Man Kin | other | 138,519 |
Our ADAG Coverage
We haven't published any research on ADAG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADAG Report →